CohBar Antifibrotic Peptide in Combination with Nintedanib Shows Enhanced Effects in an Idiopathic Pulmonary Fibrosis Model

Oct 26, 2020

CohBar to Present at the BIO-Europe Conference

Oct 15, 2020

CohBar’s CEO to Participate on the Emerging Companies Panel at the Targeting Metabesity Conference

Oct 8, 2020

CohBar to Present at the BIO Investor Forum

Oct 5, 2020

CohBar to Present at the H.C. Wainwright 4th Annual NASH Investor Conference

Sep 29, 2020

CohBar to Present at the Oppenheimer Fall Healthcare, Life Sciences, & MedTech Summit

Sep 10, 2020

CohBar to Present at the H.C. Wainwright Annual Global Investment Conference

Sep 3, 2020

CohBar Announces Closing of Public Offering of Common Stock and Warrants

Aug 28, 2020

CohBar Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants

Aug 26, 2020

CohBar Announces Proposed Public Offering of Common Stock and Warrants

Aug 25, 2020